Biology of Human Tumors PIK 3 CA Mutational Status in Circulating Tumor Cells Can Change During Disease Recurrence or Progression in Patients with Breast Cancer

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Not labeled

• Identifiers

  No identifiers available.

• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Correlation of breast cancer axillary lymph node metastases with stem cell mutations.

  2013cited by this paper
• Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies

  2013cited by this paper
• Clinical challenges in the molecular characterization of circulating tumour cells in breast cancer

  2013cited by this paper
• Targeting PI3K in Cancer: Any Good News?

  2013cited by this paper
• A Novel Fully Automated Molecular Diagnostic System (AMDS) for Colorectal Cancer Mutation Detection

  2013cited by this paper
• Novel method for PIK3CA mutation analysis: locked nucleic acid--PCR sequencing.

  2013cited by this paper
• KRAS and BRAF mutation status in circulating colorectal tumor cells and their correlation with primary and metastatic tumor tissue

  2013cited by this paper
• Heterogeneity of epidermal growth factor receptor status and mutations of KRAS/PIK3CA in circulating tumor cells of patients with colorectal cancer.

  2013cited by this paper
• SOX17 promoter methylation in circulating tumor cells and matched cell-free DNA isolated from plasma of patients with breast cancer.

  2013cited by this paper
• Detection and recovery of circulating colon cancer cells using a dielectrophoresis-based device: KRAS mutation status in pure CTCs.

  2013cited by this paper
• Complex tumor genomes inferred from single circulating tumor cells by array-CGH and next-generation sequencing.

  2013cited by this paper
• Analysis of PIK3CA exon 9 and 20 mutations in breast cancers using PCR-HRM and PCR-ARMS: correlation with clinicopathological criteria.

  2013cited by this paper
• Outcome impact of PIK3CA mutations in HER2-positive breast cancer patients treated with trastuzumab

  2013cited by this paper
• Analysing the mutational status of PIK3CA in circulating tumor cells from metastatic breast cancer patients

  2013cited by this paper
• High independent prognostic and predictive value of circulating tumor cells compared with serum tumor markers in a large prospective trial in first-line chemotherapy for metastatic breast cancer patients.

  2012cited by this paper
• Detection of Tumor PIK3CA Status in Metastatic Breast Cancer Using Peripheral Blood

  2012cited by this paper
• Influence of chemotherapy on EGFR mutation status among patients with non-small-cell lung cancer.

  2012cited by this paper
• Personalized Medicine in a Phase I Clinical Trials Program: The MD Anderson Cancer Center Initiative

  2012cited by this paper
• PTEN gene expression and mutations in the PIK3CA gene as predictors of clinical benefit to anti-epidermal growth factor receptor antibody therapy in patients with KRAS wild-type metastatic colorectal cancer.

  2012cited by this paper
• PIK3CA mutation impact on survival in breast cancer patients and in ERα, PR and ERBB2-based subgroups

  2012cited by this paper
• Circulating tumour cells in non-metastatic breast cancer: a prospective study.

  2012cited by this paper
• Clinical application of circulating tumor cells in breast cancer: overview of the current interventional trials

  2012cited by this paper
• Temperature-tolerant COLD-PCR reduces temperature stringency and enables robust mutation enrichment.

  2012cited by this paper
• Noninvasive Identification and Monitoring of Cancer Mutations by Targeted Deep Sequencing of Plasma DNA

  2012cited by this paper
• Clinical relevance of circulating CK-19mRNA-positive tumour cells before front-line treatment in patients with metastatic breast cancer

  2012cited by this paper
• Molecular characterization of circulating tumor cells in breast cancer: challenges and promises for individualized cancer treatment

  2012cited by this paper
• Trastuzumab decreases the incidence of clinical relapses in patients with early breast cancer presenting chemotherapy-resistant CK-19mRNA-positive circulating tumor cells: results of a randomized phase II study.

  2012cited by this paper
• Mutation Scanning Using MUT-MAP, a High-Throughput, Microfluidic Chip-Based, Multi-Analyte Panel

  2012cited by this paper
• Cytokeratin-19 mRNA-positive circulating tumor cells during follow-up of patients with operable breast cancer: prognostic relevance for late relapse

  2011cited by this paper
• DNA methylation of tumor suppressor and metastasis suppressor genes in circulating tumor cells.

  2011cited by this paper
• Rare allele enrichment and detection by allele-specific PCR, competitive probe blocking, and melting analysis

  2011cited by this paper
• Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment

  2011cited by this paper
• Molecular characterization of circulating tumor cells in breast cancer by a liquid bead array hybridization assay.

  2011cited by this paper
• Gene expression profile of circulating tumor cells in breast cancer by RT-qPCR

  2011cited by this paper
• PIK3CA hotspot mutation scanning by a novel and highly sensitive high-resolution small amplicon melting analysis method.

  2010cited by this paper
• Pathway-Based Identification of Biomarkers for Targeted Therapeutics: Personalized Oncology with PI3K Pathway Inhibitors

  2010cited by this paper
• Cytokeratin-19 mRNA-positive circulating tumor cells after adjuvant chemotherapy in patients with early breast cancer.

  2009cited by this paper
• Molecular characterization of circulating tumor cells in large quantities of contaminating leukocytes by a multiplex real-time PCR

  2009cited by this paper
• Molecular profiling and predictive value of circulating tumor cells in patients with metastatic breast cancer: an option for monitoring response to breast cancer related therapies

  2009cited by this paper
• Single circulating tumor cell detection and overall survival in nonmetastatic breast cancer.

  2009cited by this paper
• Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients

  2009cited by this paper
• Cancer micrometastases

  2009cited by this paper
• An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer.

  2008cited by this paper
• Detection of mutations in EGFR in circulating lung-cancer cells.

  2008cited by this paper
• Clinical relevance of circulating CK-19 mRNA-positive cells detected during the adjuvant tamoxifen treatment in patients with early breast cancer.

  2007cited by this paper
• Kappa statistic

  2005cited by this paper
• Circulating tumor cells, disease progression, and survival in metastatic breast cancer.

  2004cited by this paper
• Molecular detection of cytokeratin-19-positive cells in the peripheral blood of patients with operable breast cancer: evaluation of their prognostic significance.

  2002cited by this paper

• No citing papers are available for this paper.